Compare Neurocrine Biosciences Inc (NBIX) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Xpeng Inc - ADR — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Xpeng Inc - ADR trades at $10.63 (market cap $10.34B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals.
| NBIX | XPEV | |
|---|---|---|
Market Cap | $15.77B | $10.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $28.07 |
52-Week Low | $123.10 | $10.57 |
Enterprise Value | $15.78B | $12.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
XPeng (XPEV) trades at $10.93, down 0.18% on the day, with a bearish technical signal and negative earnings in recent quarters. The company reported a net loss of $1.14 billion in 2025 despite revenue growth to $76.72 billion, and cash flow trends show volatility. Recent news highlights expansion into humanoid robotics, with the robotics unit raising over $900 million at a $6.3 billion valuation in August 2026.
The outlook is mixed: analyst consensus is bullish with a $19.00 price target, but execution risks in the competitive EV market and persistent losses pose challenges. Robotics diversification offers long-term potential, yet near-term profitability remains uncertain amid weak delivery forecasts and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
